Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Operating Margin (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Operating Margin readings, the most recent being 60.45% for Q4 2025.

  • On a quarterly basis, Operating Margin rose 7837.0% to 60.45% in Q4 2025 year-over-year; TTM through Dec 2025 was 109.08%, a 5663.0% increase, with the full-year FY2025 number at 130.65%, up 4927.0% from a year prior.
  • Operating Margin hit 60.45% in Q4 2025 for Enanta Pharmaceuticals, up from 121.56% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 60.45% in Q4 2025 to a low of 221.7% in Q1 2023.
  • Median Operating Margin over the past 5 years was 152.03% (2021), compared with a mean of 152.93%.
  • Biggest five-year swings in Operating Margin: crashed -10453bps in 2021 and later soared 8282bps in 2025.
  • Enanta Pharmaceuticals' Operating Margin stood at 109.99% in 2021, then dropped by -16bps to 127.25% in 2022, then tumbled by -52bps to 193.78% in 2023, then increased by 28bps to 138.82% in 2024, then soared by 56bps to 60.45% in 2025.
  • The last three reported values for Operating Margin were 60.45% (Q4 2025), 121.56% (Q3 2025), and 103.16% (Q2 2025) per Business Quant data.